Erratum To: A 2-Year Observational Study of Patients with Relapsing-Remitting Multiple Sclerosis Converting to Glatiramer Acetate from Other Disease-Modifying Therapies: the Coptimize Trial (J Neurol, (2014), 261, (2101-2111), 10.1007/S00415-014-7446-0)